Chapter 6 168 ACKNOWLEDGMENTS The authors would like to thank Manou van Alphen and Wenda Verschoor for their assistance in sample measurements with IFCM, Marian C. Clahsen – van Groningen for the pathological scoring of the biopsy samples, and the Immunohaematology and Blood Transfusion lab of the Leiden University Medical Center (LUMC) for performing the Luminex single antigen assay for the HLA-A3 mAb. AUTHOR CONTRIBUTIONS W.W.W. participated in the research design, performance of the research, data analysis, article drafting and is the corresponding author. D.A.H., C.C.B., M.J.H., K.B. participated in the research design and writing of the manuscript. All authors reviewed the manuscript and approved its final version. DATA AVAILABILITY All source data underlying the figures presented in this work are provided as ‘Supplementary Data Figures 1-4’. Any other relevant data are available from the corresponding author upon reasonable request. CONFLICT OF INTEREST In the last three years, D.A. Hesselink has received lecture fees and consulting fees from Astellas Pharma, Chiesi Pharma, Medincell, Novartis Pharma, Sangamo Therapeutics and Vifor Pharma. He has received grant support from Astellas Pharma and Chiesi Pharma [paid to his institution]. D.A. Hesselink does not have employment or stock ownership at any of these companies, and neither does he have patents or patent applications. All other authors declare to not have competing interests. FINANCIAL DISCLOSURE The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
RkJQdWJsaXNoZXIy MTk4NDMw